PreferredStockChannel

Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Sun, December 5, 5:25 AM

Slide #56. VistaGen Therapeutics, Inc. Preferred Stock Offering

Company: VistaGen Therapeutics, Inc. (NASDAQ:VTGN)
Date announced: 12/17/2020
Shares Offered: 2,000,000
Date of Pricing: 12/18/2020
Price Per Share: $21.16
Preferred Stock Offering Details: VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that it commenced an underwritten public offering of units consisting of its common stock, par value $0.001 per share (the "Common Stock"), and its Series D convertible preferred stock (the "Series D Preferred Stock"). All securities to be sold in the offering are to be sold by VistaGen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 12/18- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the "Common Stock"), and 2,000,000 shares of its Series D convertible preferred stock ("Series D Preferred Stock") at a public offering price of $21.16 per share.

VistaGen Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for anxiety, depression and certain additional central nervous system disorders. Co.'s product candidates include: PH94B, which is a neuroactive nasal spray with therapeutic potential in a range of indications involving anxiety or phobia; PH10, which is a synthetic neurosteroid delivered intranasally that has therapeutic potential in a range of neuropsychiatric indications involving depression; and AV-101 (4-Cl-KYN), which is an oral prodrug that targets the N-methyl-D-aspartate receptor, an ionotropic glutamate receptor in the brain.
Open the VTGN Page at Preferred Stock Channel »

Name: 
VistaGen Therapeutics Inc
Website: 
www.vistagen.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding VTGN: 
15 (see which ones)
Total Market Value Held by ETFs: 
$30,036,200.75
Total Market Capitalization: 
$385,000,000
% of Market Cap. Held by ETFs: 
7.80%
 

Open the VTGN Page at Preferred Stock Channel (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree VTGN Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (4.00 out of 4)
74th percentile
(ranked higher than approx. 74% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com
Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 56 of 573 | www.PreferredStockChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.